{
    "info": {
        "nct_id": "NCT04335682",
        "official_title": "A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated With Darolutamide or Enzalutamide (ARACOG)",
        "inclusion_criteria": "Key inclusion criteria include:\n\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Progressive disease per PCWG3 criteria with EITHER: Metastatic CRPC or non- metastatic CRPC (M0CRPC)\n\n  * For mCRPC: metastatic disease documented by standard or novel imaging techniques\n  * OR for M0CPRC: no evidence of metastatic disease on standard imaging.\n* OR mHSPC\n* Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the patient is medically castrated, continuous dosing with GnRH agonist or antagonist must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* Able to complete cognitive testing and patient reported outcome surveys in English.\n* Ability to swallow study medications whole.\n* Able to provide informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* OR for M0CPRC: no evidence of metastatic disease on standard imaging.",
            "criterions": [
                {
                    "exact_snippets": "no evidence of metastatic disease on standard imaging",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "evidence on standard imaging",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* OR mHSPC",
            "criterions": [
                {
                    "exact_snippets": "mHSPC",
                    "criterion": "metastatic hormone-sensitive prostate cancer (mHSPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to complete cognitive testing and patient reported outcome surveys in English.",
            "criterions": [
                {
                    "exact_snippets": "Able to complete cognitive testing",
                    "criterion": "cognitive testing ability",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to complete ... patient reported outcome surveys in English",
                    "criterion": "patient reported outcome survey completion in English",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "language",
                            "expected_value": "English"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive disease per PCWG3 criteria with EITHER: Metastatic CRPC or non- metastatic CRPC (M0CRPC)",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease per PCWG3 criteria",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "per PCWG3 criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "Metastatic CRPC",
                    "criterion": "metastatic castration-resistant prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non- metastatic CRPC (M0CRPC)",
                    "criterion": "non-metastatic castration-resistant prostate cancer (M0CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to provide informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Able to provide informed consent.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability to provide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to swallow study medications whole.",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow study medications whole",
                    "criterion": "ability to swallow study medications whole",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the patient is medically castrated, continuous dosing with GnRH agonist or antagonist must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study.",
            "criterions": [
                {
                    "exact_snippets": "Surgically or medically castrated",
                    "criterion": "castration status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "surgically castrated",
                                "medically castrated"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "testosterone levels of <50 ng/dL",
                    "criterion": "testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If the patient is medically castrated, continuous dosing with GnRH agonist or antagonist must have been initiated at least 4 weeks prior to randomization",
                    "criterion": "GnRH agonist or antagonist dosing initiation",
                    "requirements": [
                        {
                            "requirement_type": "initiation time before randomization",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If the patient is medically castrated, ... must be continued throughout the study",
                    "criterion": "GnRH agonist or antagonist dosing continuation",
                    "requirements": [
                        {
                            "requirement_type": "continuation during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed adenocarcinoma of the prostate",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For mCRPC: metastatic disease documented by standard or novel imaging techniques",
            "criterions": [
                {
                    "exact_snippets": "For mCRPC: metastatic disease documented by standard or novel imaging techniques",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "standard imaging techniques",
                                "novel imaging techniques"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Key inclusion criteria include:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}